Table 2.
rs10975519 | rs16924159 | rs7044343 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | AA | AG | GG | CC | CT | TT | |||
RA | |||||||||||
Female patients | 142 (38.7%) | 188 (51.2%) | 37 (10.1%) | 52 (14.2%) | 182 (49.6%) | 133 (36.2%) | 48 (33.2%) | 197 (53.7%) | 122 (33.2%) | ||
Male patients | 43 (43.9%) | 51 (52.0%) | 4 (4.1%) | 13 (13.3%) | 46 (46.9%) | 39 (39.8%) | 7 (7.1%) | 55 (56.1%) | 36 (36.7%) | ||
Female controls | 53 (54.1%) | 34 (34.7%) | 11 (11.2%) | 16 (16.3%) | 45 (45.9%) | 13 (13.3%) | 13 (13.3%) | 44 (44.9%) | 41 (41.8%) | ||
Male controls | 51 (38.9%) | 66 (50.4%) | 14 (10.7%) | 13 (9.9%) | 66 (50.4%) | 52 (39.7%) | 18 (13.7%) | 68 (51.9%) | 45 (34.4%) | ||
AS | |||||||||||
Female patients | 7 (19.4%)a | 23 (63.9%) | 6 (16.7%) | 10 (27.8%) | 16 (44.4%) | 10 (27.8%) | 8 (22.2%)b | 22 (61.1%) | 6 (16.7%) | ||
Male patients | 47 (44.3%) | 48 (45.3%) | 11 (10.4%) | 11 (10.4%) | 57 (53.8%) | 38 (35.8%) | 18 (17.0%) | 46 (43.4%) | 42 (39.6%) | ||
Female controls | 53 (54.1%) | 34 (34.7%) | 11 (11.2%) | 16 (16.3%) | 45 (45.9%) | 37 (37.8%) | 13 (13.3%) | 44 (44.9%) | 41 (41.8%) | ||
Male controls | 51 (38.9%) | 66 (50.4%) | 14 (10.7%) | 13 (9.9%) | 66 (50.4%) | 52 (39.7%) | 18 (13.7%) | 68 (51.9%) | 45 (34.4%) | ||
PsA | |||||||||||
Female patients | 26 (41.9%) | 27 (43.5%) | 9 (14.5%) | 8 (12.9%) | 29 (46.8%) | 25 (40.3%) | 10 (16.4%) | 30 (49.2%) | 21 (34.4%) | ||
Male patients | 29 (45.3%) | 26 (40.6%) | 9 (14.1%) | 12 (18.8%) | 27 (42.2%) | 25 (39.1%) | 11 (17.2%) | 29 (45.3%) | 24 (37.5%) | ||
Female controls | 53 (54.1%) | 34 (34.7%) | 11 (11.2%) | 16 (16.3%) | 45 (45.9%) | 37 (37.8%) | 13 (13.3%) | 44 (44.9%) | 41 (41.8%) | ||
Male controls | 51 (38.9%) | 66 (50.4%) | 14 (10.7%) | 12 (18.8%) | 66 (50.4%) | 52 (39.7%) | 18 (13.7%) | 68 (51.9%) | 45 (34.4%) |
aCMH: p=0.001, pc=0.032, OR=0.47, CI95%=(0.30–0.74); groupwise (females): pc=0.002; bCMH: p = 0.001, pc = 0.027, OR = 0.46, CI95% = (0.29–0.72); groupwise (females): pc=0.038. RA, rheumatoid arthritis; AS, ankylosing spondylitis; PsA, psoriatic arthritis; CMH, Cochran-Mantel-Haenszel χ2 test; pc, value with Bonferroni correction.